Svelte Medical Systems has partnered with Asahi Intecc USA for manufacturing and co-branding of the Svelte drug-eluting coronary stent fixed wire Integrated Delivery System (IDS).
Through providing its Actone wire technology, Asahi will involve in the design and development, as well as supply core wire and coil assemblies for the Svelte IDS.
Svelte Medical Systems president and CEO Jack Darby said: "Our collaboration with Asahi Intecc takes our fixed wire stent program to the next level at a time when global support for TRI procedures and the ‘slender approach’ is growing rapidly, especially in the US."
The Svelte IDS is being developed to optimize transradial (through the wrist) interventions (TRI) and the ‘slender’ approach to percutaneous coronary intervention (PCI), noted Asahi.
Svelte is currently working with regulatory authorities to receive approval to carry out pivotal trials with the IDS in Japan and the US, and planning the commercial availability in Europe in 2015.
Asahi Intecc develops and markets guidewires and catheters used in less invasive cardiovascular, peripheral vascular, abdominal vascular and neurovascular procedures, while Svelte is involved in the development of deliverable balloon expandable stents.